Detection of adventitial vasa vasorum and intraplaque neovascularization in carotid atherosclerotic lesions with contrast-enhanced ultrasound and their role in atherosclerosis.

Sasan Partovi, Matthias Loebe, George P. Noon, Mark G. Davies, Sasan Karimi, Lisa Zipp, Steven B. Feinstein, Daniel Staub

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

INTRODUCTION: The development of new surrogate markers of atherosclerosis is a crucial goal in the clinical setting, as they may allow physicians to recognize unstable lesions early and identify individuals with vulnerable or unstable lesions who bear an increased risk of future cardio--and cerebrovascular complications. These surrogate markers should be capable of being measured noninvasively using safe and reliable methods. Recently, Nambi et al. demonstrated how the combined measurement of carotid intima media thickness (CIMT) and occurrence of carotid plaques improves the risk prediction of cardiovascular outcomes. These results confirm the value of carotid ultrasound (US) when combined with traditional Framingham risk factors in assessing a patient's risk for atherosclerotic disease. Contrast-enhanced ultrasound (CEUS) is a new imaging approach that is evolving and may become a standard clinical tool for further atherosclerotic risk stratification in the future. The contrast agents used in US imaging are safe, commercially available, and approved for use in echocardiography by the FDA. Thus, CEUS is technically feasible with existing approved commercial equipment and can be performed at the bedside or in an outpatient setting. However, US contrast agents are not yet approved by the FDA for visualization and assessment of the carotid artery and its associated pathologies. The cost effectiveness of CEUS has been shown in the context of gastrointestinal imaging, and CEUS of carotid atherosclerotic lesions is emerging as an approach to complement unenhanced US imaging. By providing the direct visualization of adventitial vasa vasorum (VV) and intraplaque neovascularization, CEUS is capable of depicting two new surrogate markers of atherosclerosis - namely, adventitial VV and intraplaque neovascularization.

Original languageEnglish (US)
Pages (from-to)37-40
Number of pages4
JournalMethodist DeBakey cardiovascular journal
Volume7
Issue number4
StatePublished - Oct 2011
Externally publishedYes

Fingerprint

Vasa Vasorum
Adventitia
Atherosclerosis
Biomarkers
Contrast Media
Ultrasonography
Carotid Intima-Media Thickness
Carotid Arteries
Cost-Benefit Analysis
Echocardiography
Outpatients
Pathology
Physicians
Equipment and Supplies

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Detection of adventitial vasa vasorum and intraplaque neovascularization in carotid atherosclerotic lesions with contrast-enhanced ultrasound and their role in atherosclerosis. / Partovi, Sasan; Loebe, Matthias; Noon, George P.; Davies, Mark G.; Karimi, Sasan; Zipp, Lisa; Feinstein, Steven B.; Staub, Daniel.

In: Methodist DeBakey cardiovascular journal, Vol. 7, No. 4, 10.2011, p. 37-40.

Research output: Contribution to journalArticle

Partovi, Sasan ; Loebe, Matthias ; Noon, George P. ; Davies, Mark G. ; Karimi, Sasan ; Zipp, Lisa ; Feinstein, Steven B. ; Staub, Daniel. / Detection of adventitial vasa vasorum and intraplaque neovascularization in carotid atherosclerotic lesions with contrast-enhanced ultrasound and their role in atherosclerosis. In: Methodist DeBakey cardiovascular journal. 2011 ; Vol. 7, No. 4. pp. 37-40.
@article{ac666e788d354425853f04913cdad5a8,
title = "Detection of adventitial vasa vasorum and intraplaque neovascularization in carotid atherosclerotic lesions with contrast-enhanced ultrasound and their role in atherosclerosis.",
abstract = "INTRODUCTION: The development of new surrogate markers of atherosclerosis is a crucial goal in the clinical setting, as they may allow physicians to recognize unstable lesions early and identify individuals with vulnerable or unstable lesions who bear an increased risk of future cardio--and cerebrovascular complications. These surrogate markers should be capable of being measured noninvasively using safe and reliable methods. Recently, Nambi et al. demonstrated how the combined measurement of carotid intima media thickness (CIMT) and occurrence of carotid plaques improves the risk prediction of cardiovascular outcomes. These results confirm the value of carotid ultrasound (US) when combined with traditional Framingham risk factors in assessing a patient's risk for atherosclerotic disease. Contrast-enhanced ultrasound (CEUS) is a new imaging approach that is evolving and may become a standard clinical tool for further atherosclerotic risk stratification in the future. The contrast agents used in US imaging are safe, commercially available, and approved for use in echocardiography by the FDA. Thus, CEUS is technically feasible with existing approved commercial equipment and can be performed at the bedside or in an outpatient setting. However, US contrast agents are not yet approved by the FDA for visualization and assessment of the carotid artery and its associated pathologies. The cost effectiveness of CEUS has been shown in the context of gastrointestinal imaging, and CEUS of carotid atherosclerotic lesions is emerging as an approach to complement unenhanced US imaging. By providing the direct visualization of adventitial vasa vasorum (VV) and intraplaque neovascularization, CEUS is capable of depicting two new surrogate markers of atherosclerosis - namely, adventitial VV and intraplaque neovascularization.",
author = "Sasan Partovi and Matthias Loebe and Noon, {George P.} and Davies, {Mark G.} and Sasan Karimi and Lisa Zipp and Feinstein, {Steven B.} and Daniel Staub",
year = "2011",
month = "10",
language = "English (US)",
volume = "7",
pages = "37--40",
journal = "Methodist DeBakey cardiovascular journal",
issn = "1947-6094",
publisher = "Methodist DeBakey Heart & Vascular Center",
number = "4",

}

TY - JOUR

T1 - Detection of adventitial vasa vasorum and intraplaque neovascularization in carotid atherosclerotic lesions with contrast-enhanced ultrasound and their role in atherosclerosis.

AU - Partovi, Sasan

AU - Loebe, Matthias

AU - Noon, George P.

AU - Davies, Mark G.

AU - Karimi, Sasan

AU - Zipp, Lisa

AU - Feinstein, Steven B.

AU - Staub, Daniel

PY - 2011/10

Y1 - 2011/10

N2 - INTRODUCTION: The development of new surrogate markers of atherosclerosis is a crucial goal in the clinical setting, as they may allow physicians to recognize unstable lesions early and identify individuals with vulnerable or unstable lesions who bear an increased risk of future cardio--and cerebrovascular complications. These surrogate markers should be capable of being measured noninvasively using safe and reliable methods. Recently, Nambi et al. demonstrated how the combined measurement of carotid intima media thickness (CIMT) and occurrence of carotid plaques improves the risk prediction of cardiovascular outcomes. These results confirm the value of carotid ultrasound (US) when combined with traditional Framingham risk factors in assessing a patient's risk for atherosclerotic disease. Contrast-enhanced ultrasound (CEUS) is a new imaging approach that is evolving and may become a standard clinical tool for further atherosclerotic risk stratification in the future. The contrast agents used in US imaging are safe, commercially available, and approved for use in echocardiography by the FDA. Thus, CEUS is technically feasible with existing approved commercial equipment and can be performed at the bedside or in an outpatient setting. However, US contrast agents are not yet approved by the FDA for visualization and assessment of the carotid artery and its associated pathologies. The cost effectiveness of CEUS has been shown in the context of gastrointestinal imaging, and CEUS of carotid atherosclerotic lesions is emerging as an approach to complement unenhanced US imaging. By providing the direct visualization of adventitial vasa vasorum (VV) and intraplaque neovascularization, CEUS is capable of depicting two new surrogate markers of atherosclerosis - namely, adventitial VV and intraplaque neovascularization.

AB - INTRODUCTION: The development of new surrogate markers of atherosclerosis is a crucial goal in the clinical setting, as they may allow physicians to recognize unstable lesions early and identify individuals with vulnerable or unstable lesions who bear an increased risk of future cardio--and cerebrovascular complications. These surrogate markers should be capable of being measured noninvasively using safe and reliable methods. Recently, Nambi et al. demonstrated how the combined measurement of carotid intima media thickness (CIMT) and occurrence of carotid plaques improves the risk prediction of cardiovascular outcomes. These results confirm the value of carotid ultrasound (US) when combined with traditional Framingham risk factors in assessing a patient's risk for atherosclerotic disease. Contrast-enhanced ultrasound (CEUS) is a new imaging approach that is evolving and may become a standard clinical tool for further atherosclerotic risk stratification in the future. The contrast agents used in US imaging are safe, commercially available, and approved for use in echocardiography by the FDA. Thus, CEUS is technically feasible with existing approved commercial equipment and can be performed at the bedside or in an outpatient setting. However, US contrast agents are not yet approved by the FDA for visualization and assessment of the carotid artery and its associated pathologies. The cost effectiveness of CEUS has been shown in the context of gastrointestinal imaging, and CEUS of carotid atherosclerotic lesions is emerging as an approach to complement unenhanced US imaging. By providing the direct visualization of adventitial vasa vasorum (VV) and intraplaque neovascularization, CEUS is capable of depicting two new surrogate markers of atherosclerosis - namely, adventitial VV and intraplaque neovascularization.

UR - http://www.scopus.com/inward/record.url?scp=84859508635&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859508635&partnerID=8YFLogxK

M3 - Article

C2 - 22143476

AN - SCOPUS:84859508635

VL - 7

SP - 37

EP - 40

JO - Methodist DeBakey cardiovascular journal

JF - Methodist DeBakey cardiovascular journal

SN - 1947-6094

IS - 4

ER -